CheckMate 816 was a phase 3, open-label trial that randomized adults with resectable stage IB (≥4 cm) to IIIA NSCLC (AJCC v7), an ECOG performance status of ≤ 1, and no known EGFR or ALK alterations to receive either the neoadjuvant nivolumab plus platinum-based chemotherapy or chemotherapy alone, both administered every three weeks for three cycles prior to surgery. The gene discussed is ALK; the disease is non-small cell lung carcinoma.